drugset
drugset / Trial / NCT07702292

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07702292 ↗

Phase 2 Recruiting 65 enrolled Blue Earth Diagnostics Medpace, Inc. · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Timeline

Start
2026-06-30
Primary completion
2028-02
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject [68Ga]BED003 Unknown — —

Indications

colorectal cancer gastric cancer invasive lobular breast carcinoma malignant epithelial tumor of ovary pancreatic ductal adenocarcinoma